Treatment with taxanes of refractory or
โ
Laurence Fardet; Pierre-Emmanuel Stoebner; Herve Bachelez; Vincent Descamps; Del
๐
Article
๐
2006
๐
John Wiley and Sons
๐
English
โ 130 KB
## Abstract ## BACKGROUND Kaposi sarcoma (KS) is an angioproliferative disease that may represent a difficult therapeutic challenge in disseminated stages. The efficacy of taxanes (paclitaxel and docetaxel), as agents with antiangiogenic properties, has been described previously in the treatment o